Virginia Medicaid Preferred Drug List (PDL) Program:
Annual Review of PDL Phase II and Review of New Drugs and Potential New Classes
Pharmacy and Therapeutics Committee Meeting
Thursday, October 23, 2008
10:00 a.m., 7th Floor Conference Rooms
DRAFT AGENDA

Welcome and Comments from DMAS' Director	**Patrick Finnerty, DMAS Director**
Comments from the Chairperson	**Randy Axelrod, M.D., Chairman**
Acceptance of Minutes From April 22, 2008 P&T Meeting	**P&T Committee Members**
Review of Draft Generic Drug Policy*	**P&T Committee Members**
Clinical Class Review of Oral Hypoglycemic	**Randy Axelrod, M.D., Chairman** **Consultant – TBD**
Drug Class Discussions	**P&T Committee Members**

Review of New Drugs in PDL Phase II

Antibiotics – Antiinfectives-Cephalosporins
- Cefuroxime axetil suspension (New generic for Ceftin)

Serotonin Receptor Agonists (Triptans)
- TREXIMET®

Diabetes Oral Hypoglycemics Combinations
- PrandiMet®

Stimulants/ADHD Medications
- LiquADD®

Re-review of Generic Pricing in PDL Phase II

All Osteoporosis-Bisphosphonates Products

Phase I PDL Annual Review

Antivirals
- Hepatitis C

Asthma –Allergy
- Antihistamines – 2nd generation (includes combination products)
- Beta Adrenergics- (includes short acting, long acting, nebulized and combinations)
- COPD Anticholinergics
- Inhaled corticosteroids
- Nasal steroids

Cardiac Medications
- ACE inhibitors (includes combination products with HCTZ & CCB)

Cardiac Medications (con't)
- Angiotensin receptor antagonists - ARB (includes combination products with HCTZ & CCB, as well as Renin inhibitors)
- Beta blockers
- Calcium channel blockers (includes dihydropyridine & Non-dihydropyridine agents)
- Lipotropics (Includes HMG CoA Reductase Inhibitors-Statins, Fibric Acid Derivatives, Omega 3 agents, Niacin derivatives, Niacin/Statin Combinations and CAI agent)

Phase I PDL Annual Review (continued)

Cardiac Medications (con't)
- PDE-5 inhibitors- pulmonary hypertension

Central Nervous System
- Sedative Hypnotic
- Other Sedative Hypnotic

Gastrointestinal
- Histamine-2 Receptor Antagonists (H2RA)
- Proton Pump Inhibitors

Genitourinary
- Urinary Antispasmodics

Miscellaneous
- Electrolyte Depleters
- Topical Immunomodulators
- Growth hormone

Confidential Meeting	**Confidential Meeting for P&T Committee Members, DMAS, and FHSC Pursuant to 42 U.S.C. § 1396r-8 to discuss pricing information**
Criteria Discussion of Phase II New Drugs**	**P&T Committee Members**
Criteria Discussion for PDL Phase I Drug Classes**	**P&T Committee Members**
Next Meeting – TBD	**Randy Axelrod, M.D., Chairman**

Public comments will be accepted on the Draft Generic Drug Policy. This document reflects more concisely the information contained in the final Guidance Document Regarding New Generic Drug Policy, which was approved by the P&T Committee on April 22, 2008. The Draft Generic Drug Policy may be found on the DMAS web site at the following link:* http://www.dmas.virginia.gov/pharm-p&t_committee.htm . ***Written comments and requests to present on the Draft Generic Drug Policy during the meeting must be submitted by COB Tuesday, October 14, 2008. Requests to present should include the name, title, and affiliation of the presenter.*

***Criteria discussions will be held for classes only if deemed PDL eligible by the P&T Committee during Drug Class Discussions.*

Oral presentations: The P&T Committee in conjunction with the Department will be allocating time slots for interested parties to present scientific and clinical information on ***only*** the drug classes subject to PDL Phase II annual review, potential new drug classes, and specific new drugs in PDL Phase I classes listed on the Agenda. All presentations must include newly published information (per guidelines below) that is clinical in nature and based on scientific material. The references used to authorize presentations must be within the following timeframes:

- PDL Phase I Annual Review – October 2007 to present
- New Drugs in PDL Phase II Drug Classes – April 2007 to present

No anecdotal accounts are to be given. Each speaker will be allocated no more than 3 minutes to present. The actual speakers will be decided by the Chairperson based on relevancy of the information. Speakers must receive a confirmation number to verify the presentation is scheduled.

If you are interested in providing specific clinical information to the Committee at the meeting, please submit an outline of discussion points, clinical references (within the stated guidelines above) and a written request to speak with the name/title of the presenter. Please send information to pdlinput@dmas.virginia.gov **by COB Thursday, October 2, 2008**.

Written information/comments: The P&T Committee will also accept written comments for consideration. Please send statements to pdlinput@dmas.virginia.gov **by COB Thursday, October 2, 2008**.